中文名稱:Cyclopamine | 英文名稱:Cyclopamine |
CAS:4449-51-8 | 品牌: 一研 |
保存條件: Store at -20°C | 產(chǎn)品類別: 抑制劑 |
Cas : 4449-51-8 |
產(chǎn)品屬性:
產(chǎn)品名稱 | 規(guī)格 | CAS號(hào) | 型號(hào) |
Cyclopamine | 5mg 10mg 25mg 500mg 1g | 4449-51-8 | EY-Y0164738 |
Cas No.4449-51-8
別名 11-Deoxojervine
化學(xué)名 (3S,3'R,3'aS,6'S,6aS,6bS,7'aR,9R,11aS,11bR)-3',6',10,11b-tetramethylspiro[2,3,4,6,6a,6b,7,8,11,11a-decahydro-1H-benzo[a]fluorene-9,2'-3a,4,5,6,7,7a-hexahydro-3H-furo[3,2-b]pyridine]-3-ol
分子式 C27H41NO2
分子量 411.62
溶解度 ≥ 6.9mg/mL in DMSO
儲(chǔ)存條件 Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
產(chǎn)品描述:
Cyclopamine is a naturally occurring Hedgehog (Hh)?specific small?molecule signaling steroidal alkaloid inhibitor, causes a profound inhibition of tumor growth, has significant anti?invasive, anti?proliferative and anti?estrogenic potency in human breast cancer cells [2] [1]. The EC50 of cyclopamine is 10.57 μM, it was identified by an FXR-bla (farnesoid X receptor- b-lactamase) assay [3].
Hh signaling pathway plays a critical role in embryonic development and tumorigenesis [4]. Hh signaling pathway shows saliency in regulating cellular proliferation and differentiation in a wide array of human tissues. It is related to aberrant cell survival in numerous human malignancies, ranging from BCCs and medulloblastomas to small cell lung, gastrointestinal, breast and prostate tumors [1].
Treated with cyclopamine (10 or 20 μM) only and incubated for time periods ranging from 0 to10 days, MCF-7 cells and MDA?MB?231 cells displayed a significant reduction in proliferation rate compared with the control cells on days 3 and 6 (P<0.01). In the MCF?7 cells, cyclopamine significantly induced cell accumulation in the G1 phase (P<0.01) and a modest decrease in the S population percentage, from 22 to 16% (P<0.01). In the MDA?MB?231 cells, cyclopamine caused a significant increase in G1 cells. The invasion rate of cyclopamine?treated MCF?7 and MDA?MB?231cells significantly decreased compared with the CK [2].
Embryoes exposed to cyclopamine resulted in visible external defects, including cyclopia, proboscis formation, microphthalmia, thoracic lordosis, amelia and decreased body size. Examination of gastrointestinal organs revealed severe deficits, including less length of the gut tube and mesenchymal cell numbers in foregut-derived organs. Ectopic structures in duodenum, stomach, and dorsal pancreas were also found [5].
References:
[1]. Marc J. Meth and Jeffrey M. Weinberg. Cyclopamine: Inhibiting Hedgehog in the Treatment of Psoriasis. Continuing Medical Education, 2006, 78: 185-188.
[2]. Jun Che, Fu-Zheng Zhang, Chao-Qian Zhao, et al. Cyclopamine is a novel Hedgehog signaling inhibitor with significant anti?proliferative, anti?invasive and anti?estrogenic potency in human breast cancer cells. Oncology Letters, 2013, 5: 1417-1421.
[3]. Chia-Wen Hsu, Jinghua Zhao, Ruili Huang, et al. Quantitative High-Throughput Profiling of Environmental Chemicals and Drugs that Modulate Farnesoid X Receptor. Scientific Reports, 2014, 4: 6437.
[4]. Robert J. Lipinski, Paul R. Hutson, Paul W. Hannam, et al. Dose- and Route-Dependent Teratogenicity, Toxicity, and Pharmacokinetic Profiles of the Hedgehog Signaling Antagonist Cyclopamine in the Mouse. Toxicological Sciences, 2008, 104(1):189-197.
[5]. Seung K. Kim and Douglas A. Melton. Pancreas development is promoted by cyclopamine, a Hedgehog signaling inhibitor. Proc. Natl. Acad. Sci. USA, 1998, 95: 13036-13041.
成立日期 | 2014-06-05 (11年) | 注冊資本 | 100 |
員工人數(shù) | 50-100人 | 年?duì)I業(yè)額 | ¥ 100萬以內(nèi) |
主營行業(yè) | 生化試劑,抗體,細(xì)胞培養(yǎng),分子生物學(xué),免疫安全 | 經(jīng)營模式 | 工廠,試劑 |
產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
---|---|---|---|---|
¥280.00 |
VIP13年
|
南京春秋生物工程有限公司
|
2025-04-18 | |
¥450 |
VIP4年
|
上海莫奇生物科技有限公司
|
2025-04-18 | |
詢價(jià) |
VIP16年
|
上海佰世凱化學(xué)科技有限公司
|
2025-04-17 | |
詢價(jià) |
VIP1年
|
湖北萃園生物科技有限公司
|
2025-04-17 | |
詢價(jià) |
VIP4年
|
武漢艾美捷科技有限公司
|
2025-04-16 | |
詢價(jià) |
VIP7年
|
南京道斯夫生物科技有限公司
|
2025-04-06 | |
¥1317.90 |
VIP13年
|
上海阿拉丁生化科技股份有限公司
|
2025-03-24 | |
¥484 |
VIP12年
|
上海陶術(shù)生物科技有限公司
|
2025-03-12 | |
詢價(jià) |
VIP5年
|
陜西締都醫(yī)藥化工有限公司
|
2025-03-06 | |
詢價(jià) |
南京百鑫德諾生物科技有限公司
|
2024-09-26 |